Corbus Pharmaceuticals Holdings (CRBP) 2025 Conference Transcript

Summary of Corbus Pharmaceuticals Holdings (CRBP) 2025 Conference Call Company Overview - Corbus Pharmaceuticals is a drug discovery and development company based in Norwood, Massachusetts, with a team of approximately 33 employees [4][5] - The company has a pipeline consisting of three clinical assets: two in oncology and one in obesity, all of which are expected to have clinical readouts in the second half of 2025 [4][5] Key Points on Oncology Programs - The company is currently optimizing doses for its oncology program, specifically for MUC, cervical, and head and neck cancers, with results anticipated in Q4 2025 [6][7] - The focus is on three tumor types, with a significant number of patients expected to be presented at an upcoming oncology conference [8][12] - The company does not prioritize bladder cancer due to competition from established therapies like PADCEV plus Keytruda [9][10] - Benchmarks for head and neck and cervical cancers are established, with expected overall response rates (ORR) of 36% and 24%, respectively [10][11] Collaboration with CSPC - Corbus has a positive and constructive relationship with its partner CSPC, which is expected to present dose optimization data in the second half of the year [14][15] - The company has observed significant differences in patient management and trial design between the U.S. and China, particularly regarding patient adherence and quality of life considerations [17][18][19] Insights on Clinical Practices - The cultural differences in clinical practices between the West and China have led to lower discontinuation rates in Chinese trials compared to U.S. trials [17][19][20] - The company is focused on ensuring patient comfort while maintaining adherence to the study protocols [20][21] Obesity Program (CB1 Inverse Agonist) - The obesity program is entering a phase where data from a SAD/MAD study in healthy volunteers is expected, which will inform the next steps in the development plan [27][29] - The company anticipates that the obesity drug will lead to weight loss, supported by a clinically validated mechanism of action [30][31] - The focus is on ensuring a clean safety profile, particularly concerning neuropsychiatric adverse events [31][34] Competitive Landscape in Obesity - The obesity market is competitive, dominated by incretin-based therapies, but Corbus aims to position its CB1 inverse agonist as a complementary option for patients who are intolerant to existing therapies [50][54] - The potential for the drug to serve as a maintenance therapy after initial weight loss with injectable therapies is highlighted as a significant market opportunity [55][56] Financial Position - Corbus ended the quarter with $133 million in cash, providing a runway until mid-2027 [57] Future Outlook - The company is preparing for a monotherapy dose escalation study for its highest-risk program targeting TGF beta, with data expected by the end of the year [58][59]